These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. The potent in vitro skin permeation of archaeosome made from lipids extracted of Sulfolobus acidocaldarius. Moghimipour E; Kargar M; Ramezani Z; Handali S Archaea; 2013; 2013():782012. PubMed ID: 24453698 [TBL] [Abstract][Full Text] [Related]
48. In vitro assessment of archaeosome stability for developing oral delivery systems. Patel GB; Agnew BJ; Deschatelets L; Fleming LP; Sprott GD Int J Pharm; 2000 Jan; 194(1):39-49. PubMed ID: 10601683 [TBL] [Abstract][Full Text] [Related]
49. Development of new glycosylation methodologies for the synthesis of archaeal-derived glycolipid adjuvants. Whitfield DM; Yu SH; Dicaire CJ; Sprott GD Carbohydr Res; 2010 Jan; 345(2):214-29. PubMed ID: 20004891 [TBL] [Abstract][Full Text] [Related]
50. Archaeosomes: an excellent carrier for drug and cell delivery. Kaur G; Garg T; Rath G; Goyal AK Drug Deliv; 2016 Sep; 23(7):2497-2512. PubMed ID: 25777339 [TBL] [Abstract][Full Text] [Related]
52. Homologous Prime-Boost Vaccination with OVA Entrapped in Self-Adjuvanting Archaeosomes Induces High Numbers of OVA-Specific CD8⁺ T Cells that Protect Against Subcutaneous B16-OVA Melanoma. Stark FC; McCluskie MJ; Krishnan L Vaccines (Basel); 2016 Nov; 4(4):. PubMed ID: 27869670 [TBL] [Abstract][Full Text] [Related]
53. Preparation, characterization, and in vitro evaluation of isoniazid and rifampicin-loaded archaeosomes. Attar A; Bakir C; Yuce-Dursun B; Demir S; Cakmakci E; Danis O; Birbir M; Ogan A Chem Biol Drug Des; 2018 Jan; 91(1):153-161. PubMed ID: 28667670 [TBL] [Abstract][Full Text] [Related]
54. Synthesis of archaeal glycolipid adjuvants-what is the optimum number of sugars? Whitfield DM; Eichler EE; Sprott GD Carbohydr Res; 2008 Sep; 343(14):2349-60. PubMed ID: 18667197 [TBL] [Abstract][Full Text] [Related]
55. The potent adjuvant activity of archaeosomes correlates to the recruitment and activation of macrophages and dendritic cells in vivo. Krishnan L; Sad S; Patel GB; Sprott GD J Immunol; 2001 Feb; 166(3):1885-93. PubMed ID: 11160236 [TBL] [Abstract][Full Text] [Related]
56. Combinations of nanovesicles and physical methods for enhanced transdermal delivery of a model hydrophilic drug. Zorec B; Zupančič Š; Kristl J; Pavšelj N Eur J Pharm Biopharm; 2018 Jun; 127():387-397. PubMed ID: 29581043 [TBL] [Abstract][Full Text] [Related]
58. The role of formulation and follicular pathway in voriconazole cutaneous delivery from liposomes and nanostructured lipid carriers. Santos GA; Angelo T; Andrade LM; Silva SMM; Magalhães PO; Cunha-Filho M; Gelfuso GM; Taveira SF; Gratieri T Colloids Surf B Biointerfaces; 2018 Oct; 170():341-346. PubMed ID: 29940500 [TBL] [Abstract][Full Text] [Related]
59. Synthetic archaeosome vaccines containing triglycosylarchaeols can provide additive and long-lasting immune responses that are enhanced by archaetidylserine. Sprott GD; Yeung A; Dicaire CJ; Yu SH; Whitfield DM Archaea; 2012; 2012():513231. PubMed ID: 23055819 [TBL] [Abstract][Full Text] [Related]
60. In vivo investigation of twin-screw extruded lipid implants for vaccine delivery. Even MP; Young K; Winter G; Hook S; Engert J Eur J Pharm Biopharm; 2014 Jul; 87(2):338-46. PubMed ID: 24607791 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]